Q4 2025 Kestra Medical Technologies Ltd Earnings Call Transcript
Key Points
- Kestra Medical Technologies Ltd (KMTS) reported a 71% increase in revenue for the fourth quarter, reaching $17.2 million, driven by a 43% year-over-year increase in prescriptions.
- The company achieved significant gross margin expansion, with fourth-quarter gross margin at 44.3%, up from 13.9% in the prior year.
- Kestra's ASSURE system has shown high patient compliance, with a median daily use of 23.2 hours and a first shock conversion efficacy of approximately 96%.
- The company has expanded its sales territories by 67% year-over-year, aiming to further penetrate existing accounts and target new prescribers.
- Kestra has secured a sole source contract with a risk-bearing provider network, indicating recognition of the ASSURE system's benefits by payers and prescribers.
- Despite strong revenue growth, Kestra reported a GAAP net loss of $51.1 million for the fourth quarter, compared to a $22.3 million loss in the prior-year period.
- Operating expenses increased to $55.8 million in the fourth quarter, partly due to stock-based compensation and professional services expenses related to the IPO.
- The company faces challenges with underutilization of WCD therapy, reaching only 14% of the eligible US patient population.
- Kestra's adjusted EBITDA loss was $20.3 million in the fourth quarter, higher than the $16.5 million loss in the prior-year period.
- The company anticipates stock-based compensation to contribute approximately $40 million to GAAP operating expenses in fiscal year 2026, impacting profitability.
Good afternoon and welcome to Kestra Medical Technologies' fourth-quarter fiscal 2025 earnings conference call. This conference call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Neil Bhalodkar, Vice President of Investor Relations. Please go ahead.
Thank you for joining Kestra's fourth-quarter fiscal 2025 earnings call. With me today are Brian Webster, President and Chief Executive Officer; and Vaseem Mahboob, Chief Financial Officer.
This call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements. These statements are based on Kestra's current expectations, forecasts, and assumptions which are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
Actual outcomes and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
